The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action
about
sameAs
Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activityOpposing activities of two novel members of the IL-1 ligand family regulate skin inflammationIL-1 receptor 2 (IL-1R2) and its role in immune regulationDeconstructing innate immune signaling in myelodysplastic syndromesStructural insights into the assembly and activation of IL-1β with its receptorsDesign of a superior cytokine antagonist for topical ophthalmic useIL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cellsA comparative analysis of gene expression patterns and cell phenotypes between cervical and peripheral blood mononuclear cells.Different Regulation of Interleukin-1 Production and Activity in Monocytes and Macrophages: Innate Memory as an Endogenous Mechanism of IL-1 Inhibition.Blood soluble interleukin 1 receptor accessory protein levels are consistently low throughout the menstrual cycle of women with endometriosis.A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.Plasma levels of soluble interleukin 1 receptor accessory protein are reduced in obesity.The interleukin-1 family: back to the futureSoluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in miceProteomics reveals the effects of sustained weight loss on the human plasma proteomeMost recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis.Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatmentExtracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR.Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma.A single-nucleotide polymorphism in the interleukin-1 receptor-associated protein gene is associated with impaired glucose regulation and type 2 diabetes in a case-controlled study.Blocking IL-1 in systemic inflammationInhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP).Decoys and Regulatory "Receptors" of the IL-1/Toll-Like Receptor Superfamily.Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease.Alternative splicing in the NF-kappaB signaling pathway.In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromesTargeting the IL-1 family members in skin inflammation.Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review.Neutrophils, IL-1β, and gout: is there a link?Acid-dependent Interleukin-1 (IL-1) Cleavage Limits Available Pro-IL-1β for Caspase-1 Cleavage.Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia.Cytokine decoy and scavenger receptors as key regulators of immunity and inflammation.Intracellular interleukin (IL)-1 family cytokine processing enzyme.Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures.Human chorionic gonadotropin regulates endothelial cell responsiveness to interleukin 1 and amplifies the cytokine-mediated effect on cell proliferation, migration and the release of angiogenic factors.Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis.Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis.
P2860
Q24630062-5029085D-E89D-477E-95E1-44AC7CCD1929Q24676343-5FE79C91-4660-4F6A-8294-33B2DEC324A8Q26826872-B4B182E8-E8C7-46B7-B323-6A6F4D0F849BQ26991974-C976E3A2-3665-41BF-A2B9-8F0CA581CA07Q27664215-24049C6C-CF64-4E0D-8359-19C9600E6FC3Q27676526-71D84C67-5957-4619-9BBF-948BB65FCB12Q28513686-5C67FA52-B78D-4BA7-881D-7C1718872390Q33518544-2C180E11-7AFF-447E-B038-7DC44247A1A6Q33774843-C4C2A791-F82E-4A45-8BBB-F5D3E96036E4Q33811574-959A8E3A-102B-49B4-90A6-292F6A45DEACQ33921027-5393F683-B433-4730-9AFA-C0F0728E8043Q33967100-1FF6FEFF-C6A4-4858-BCE6-9FF0199949FFQ34130963-A662DD15-77CA-44D0-870C-3F983A9C4240Q34391415-07182B2A-CD53-4801-99F9-E9BD10A70149Q34451078-919D88C5-36A4-4DBC-8902-BE3265FB686FQ34547857-BCB89F41-1668-4308-A991-D18F63C10B3AQ34896866-08A6AF37-369C-4F9E-A001-7E7D2866364BQ35016953-8CF12627-D4C7-4A90-9B93-48559F50D01EQ35092966-ED4E48BE-A570-4A91-9080-6C353F50CE20Q35165663-D3CC11E5-E562-4247-BF25-60013EEFEB49Q35606790-CC387B4E-99DF-4470-B28F-CAFE15E9BF35Q35788358-8EAF1F3B-D583-4FC0-8F73-6158E690F43FQ35803472-1A52DC5E-A185-4517-BADA-EC9895BCB108Q36113777-031B790C-6DE8-4238-B5DE-99233A713BEDQ36588937-74BC4A96-828E-49C5-AF8C-4EFB0AF4997EQ36994635-F60EE977-5F86-46ED-BACA-7D7CAF66AE20Q36994761-F82C835A-B51B-4E4E-BD38-FD31015877EBQ37057998-77234285-C5D9-492E-B0A2-265804218513Q37273133-D719FC7B-60CF-4C42-914E-D0EF18F3EC2AQ37820911-4E9C759D-2DBD-4256-971F-D0C3A100FA50Q38006975-D8A45472-6952-491D-91F7-BAD1E10DB733Q38076334-F60E383F-C37A-4D69-890F-F684AFCF5642Q38839187-FCC9BE21-18EA-4118-AC16-181A31235E5EQ38908298-DC13AA69-3C9D-48BE-8327-6493586B6112Q38920969-7DE87275-4B87-4853-8AA8-6DBDD70EC2CCQ39003490-2AF0A686-5291-4047-B593-A603015048D3Q39059671-10FBC800-1B9F-4AEC-8377-BA517C3FC15EQ39204587-1CA1ECCB-AC39-4548-B514-F949CB339292Q40421570-1E411F6F-EBA5-4C26-9BB2-4893698D0605Q40626338-36F4DAC6-3269-4AD0-BF18-7C95BA225C92
P2860
The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@ast
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@en
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@nl
type
label
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@ast
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@en
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@nl
prefLabel
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@ast
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@en
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@nl
P2093
P1433
P1476
The soluble form of IL-1 recep ...... eceptor to inhibit IL-1 action
@en
P2093
Ann M Farese
Della Friend
Dirk E Smith
G Duke Virca
Heather Moore
Hongbo Chen
John E Sims
Roberta Hanna
Thomas J MacVittie
P356
10.1016/S1074-7613(02)00514-9
P407
P577
2003-01-01T00:00:00Z